Lingling Chen, Jinxia Wang, Yanping Gao, Wenbo Xiu, Zuo Wang, Gao Zhang, An Li, Yang Chen, Bolin Deng, Fang Lu, Chong He, Lijuan Hu
{"title":"分析MPO水平与青光眼严重程度的关系。","authors":"Lingling Chen, Jinxia Wang, Yanping Gao, Wenbo Xiu, Zuo Wang, Gao Zhang, An Li, Yang Chen, Bolin Deng, Fang Lu, Chong He, Lijuan Hu","doi":"10.1080/17520363.2025.2523236","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To explore the relationship between plasma myeloperoxidase (MPO) and glaucoma, assessing the clinical utility of MPO in glaucoma.</p><p><strong>Methods: </strong>A cross-sectional study involved 127 glaucoma patients and 106 healthy controls. Plasma MPO markers were quantified using enzyme-linked immunosorbent assay (ELISA), comparing levels between glaucoma patients and healthy controls, and analyzing plasma MPO across different glaucoma severity grades.</p><p><strong>Results: </strong>In this study, we observed elevated plasma MPO levels in glaucoma patients (<i>p</i> < 0.001). After correcting for confounders such as age, sex, hypertension, and diabetes, plasma MPO remained independently associated with glaucoma (OR = 1.05, 95% CI: 1.04-1.07, <i>p</i> < 0.001). Plasma MPO may reflect the severity of glaucoma, with significant differences in plasma MPO observed between early and severe stages, but not in the moderate stages. In addition, elevated plasma MPO was associated with higher cup-to-disc ratios. ROC curve analysis demonstrated the validity of glaucoma markers in identifying early glaucoma from severe glaucoma (early versus severe: AUC = 0.633).</p><p><strong>Conclusion: </strong>Elevated plasma MPO levels are independently associated with glaucoma risk, suggesting it might provide insight into disease pathogenesis.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"597-604"},"PeriodicalIF":1.9000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12258260/pdf/","citationCount":"0","resultStr":"{\"title\":\"Analyzing the association between MPO levels and glaucoma severity.\",\"authors\":\"Lingling Chen, Jinxia Wang, Yanping Gao, Wenbo Xiu, Zuo Wang, Gao Zhang, An Li, Yang Chen, Bolin Deng, Fang Lu, Chong He, Lijuan Hu\",\"doi\":\"10.1080/17520363.2025.2523236\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>To explore the relationship between plasma myeloperoxidase (MPO) and glaucoma, assessing the clinical utility of MPO in glaucoma.</p><p><strong>Methods: </strong>A cross-sectional study involved 127 glaucoma patients and 106 healthy controls. Plasma MPO markers were quantified using enzyme-linked immunosorbent assay (ELISA), comparing levels between glaucoma patients and healthy controls, and analyzing plasma MPO across different glaucoma severity grades.</p><p><strong>Results: </strong>In this study, we observed elevated plasma MPO levels in glaucoma patients (<i>p</i> < 0.001). After correcting for confounders such as age, sex, hypertension, and diabetes, plasma MPO remained independently associated with glaucoma (OR = 1.05, 95% CI: 1.04-1.07, <i>p</i> < 0.001). Plasma MPO may reflect the severity of glaucoma, with significant differences in plasma MPO observed between early and severe stages, but not in the moderate stages. In addition, elevated plasma MPO was associated with higher cup-to-disc ratios. ROC curve analysis demonstrated the validity of glaucoma markers in identifying early glaucoma from severe glaucoma (early versus severe: AUC = 0.633).</p><p><strong>Conclusion: </strong>Elevated plasma MPO levels are independently associated with glaucoma risk, suggesting it might provide insight into disease pathogenesis.</p>\",\"PeriodicalId\":9182,\"journal\":{\"name\":\"Biomarkers in medicine\",\"volume\":\" \",\"pages\":\"597-604\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12258260/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers in medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17520363.2025.2523236\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2523236","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Analyzing the association between MPO levels and glaucoma severity.
Aim: To explore the relationship between plasma myeloperoxidase (MPO) and glaucoma, assessing the clinical utility of MPO in glaucoma.
Methods: A cross-sectional study involved 127 glaucoma patients and 106 healthy controls. Plasma MPO markers were quantified using enzyme-linked immunosorbent assay (ELISA), comparing levels between glaucoma patients and healthy controls, and analyzing plasma MPO across different glaucoma severity grades.
Results: In this study, we observed elevated plasma MPO levels in glaucoma patients (p < 0.001). After correcting for confounders such as age, sex, hypertension, and diabetes, plasma MPO remained independently associated with glaucoma (OR = 1.05, 95% CI: 1.04-1.07, p < 0.001). Plasma MPO may reflect the severity of glaucoma, with significant differences in plasma MPO observed between early and severe stages, but not in the moderate stages. In addition, elevated plasma MPO was associated with higher cup-to-disc ratios. ROC curve analysis demonstrated the validity of glaucoma markers in identifying early glaucoma from severe glaucoma (early versus severe: AUC = 0.633).
Conclusion: Elevated plasma MPO levels are independently associated with glaucoma risk, suggesting it might provide insight into disease pathogenesis.
期刊介绍：
Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.
Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.
As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.
Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.
Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
